Lebrikizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Lebrikizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
59
Registered trials
96
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Lebrikizumab can convert its Monoclonal antibody profile and IL-13 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Lebrikizumab (query alias: lebrikizumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-13; IL-13 inhibitors |
| Highest global status | Approved |
| Originator | Genentech, Inc. |
| Active developers | Eli Lilly & Co., Almirall SA, Eli Lilly and Company (NZ) Limited |
The MCP disease footprint includes Dermatitis, Atopic, Nummular eczema, Chronic rhinosinusitis with nasal polyps. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07006792 | Phase 4 | Active, not recruiting | 233 | Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline |
| NCT07352566 | Phase 4 | Not yet recruiting | 10 | Number of participants with adverse events |
| NCT07542483 | Phase 3 | Not yet recruiting | 270 | Percentage of Participants Achieving Investigator Global Assessment (IGA) Score of 0 or 1 and a >=2-point Reduction from Baseline at Week 24 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are On Inhaled Corticosteroids and a Second Controller Medication.
Phase 3; n=346; evaluation: not stated. Reported fields: Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period = 0.43 events per patient year ; Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period = 0.21 events per patient year ; Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period: Adjusted Rate Ratio = 0.60(95% CI, 0.35 - 1.03); Adjusted Rate Ratio = 0.49(95% CI, 0.28 - 0.83)
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
Phase 3; n=267; evaluation: Positive. Reported fields: AE = Most adverse events (AEs) were mild (29.2%) or moderate (33.3%) in severity.
Lebrikizumab demonstrated consistent effectiveness in patients with and without prior exposure to advanced systemic therapies: interim analysis of the non-interventional study AD-LIFE
Not Applicable; n=100; evaluation: Positive. Reported fields: EASI(16-week) = -76.0 % ; EASI(16-week) = -54.4 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Lebrikizumab addresses Dermatitis, Atopic, Nummular eczema, Chronic rhinosinusitis with nasal polyps. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-01-10 | Lilly Completes Acquisition of Dermira | Approved | US$1,100.0M stated total |
| 2019-02-12 | Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab | Phase 2 | US$30.0M upfront; US$165.0M milestones; US$195.0M stated total |
| 2017-08-08 | Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab | Phase 2 | US$80.0M upfront; US$1,275.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Compositions and methods comprising combinations of TSLP and il-13 antibodies”. The milestone feed surfaced a patent-application signal described as “Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin”. The milestone feed surfaced a patent-application signal described as “Il-13 antibodies for the treatment of atopic dermatitis”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
